Charmacy Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Charmacy Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	15.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Charmacy Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2289 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	4,482	52	-63	-42	N/A
3/31/2024	4,443	52	-100	-69	N/A
12/31/2023	4,404	51	-137	-97	N/A
9/30/2023	4,480	74	-163	-125	N/A
6/30/2023	4,557	96	-190	-153	N/A
3/31/2023	4,366	93	-77	-55	N/A
12/31/2022	4,175	90	35	44	N/A
9/30/2022	3,931	54	44	51	N/A
6/30/2022	3,688	18	53	59	N/A
3/31/2022	3,741	20	4	20	N/A
12/31/2021	3,794	23	-45	-20	N/A
9/30/2021	3,959	29	75	111	N/A
6/30/2021	4,124	36	195	241	N/A
3/31/2021	4,058	38	137	186	N/A
12/31/2020	3,992	41	79	131	N/A
9/30/2020	3,819	35	-100	-37	N/A
6/30/2020	3,645	29	-280	-205	N/A
3/31/2020	3,569	34	-175	-101	N/A
12/31/2019	3,493	40	-70	4	N/A
9/30/2019	3,557	41	-31	44	N/A
6/30/2019	3,621	42	7	84	N/A
3/31/2019	3,778	44	-21	66	N/A
12/31/2018	3,935	45	-49	49	N/A
9/30/2018	4,075	46	-122	6	N/A
6/30/2018	4,214	47	-196	-37	N/A
3/31/2018	4,155	46	N/A	-35	N/A
12/31/2017	4,096	45	N/A	-33	N/A
9/30/2017	3,946	54	N/A	-82	N/A
6/30/2017	3,796	63	N/A	-130	N/A
3/31/2017	3,733	60	N/A	-116	N/A
12/31/2016	3,670	56	N/A	-102	N/A
9/30/2016	3,605	47	N/A	-27	N/A
6/30/2016	3,540	38	N/A	47	N/A
3/31/2016	3,468	32	N/A	120	N/A
12/31/2015	3,397	26	N/A	194	N/A
9/30/2015	3,299	31	N/A	156	N/A
6/30/2015	3,200	35	N/A	119	N/A
3/31/2015	3,107	36	N/A	52	N/A
12/31/2014	3,014	36	N/A	-15	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2289's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 2289's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2289's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2289's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2289's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 2289's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/01 06:52
End of Day Share Price	2025/01/28 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Charmacy Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Charmacy Pharmaceutical Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Charmacy Pharmaceutical Co., Ltd. Provides Financial Guidance for the 11 Months Ended 30 November 2022

Charmacy Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Ended 31 December 2021

Recent updates

Less than half of directors are independent

Investor sentiment improves as stock rises 17%

First half 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 1H 2023)

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Investor sentiment deteriorates as stock falls 34%

Upcoming dividend of CN¥0.30 per share

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

New major risk - Share price stability

Investor sentiment improves as stock rises 41%

New major risk - Financial position

Charmacy Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 10 July 2024

Charmacy Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 18%

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Investor sentiment improves as stock rises 31%

Investor sentiment improves as stock rises 19%

New major risk - Earnings quality

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

First half 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.19 in 1H 2022)

Investor sentiment improves as stock rises 23%

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 26, 2023

Upcoming dividend of HK$0.50 per share at 6.0% yield

Charmacy Pharmaceutical Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023

Charmacy Pharmaceutical Co., Ltd. Announces Board Changes

Upcoming dividend of CN¥0.45 per share at 6.2% yield

Charmacy Pharmaceutical Co., Ltd. Announces Ordinary Final Dividend for the Year Ended 31 December 2022, Payable on July 31, 2023

Charmacy Pharmaceutical Co., Ltd. Provides Financial Guidance for the 11 Months Ended 30 November 2022

Less than half of directors are independent

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.24 in 1H 2021)

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2022 Results on Aug 31, 2022

Charmacy Pharmaceutical Co., Ltd. Announces Executive Changes

Investor sentiment improved over the past week

Insufficient new directors

Charmacy Pharmaceutical Co., Ltd. Announces Change in Board of Directors and Composition of Board Committees

Full year 2021 earnings released

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on Mar 31, 2022

Investor sentiment deteriorated over the past week

Charmacy Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Ended 31 December 2021

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.24 (vs CN¥0.29 in 1H 2020)

First half 2021 earnings released: EPS CN¥0.24 (vs CN¥0.29 in 1H 2020)

Charmacy Pharmaceutical Co., Ltd. to Distribute the Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of CN¥0.20 per share

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

Full year 2020 earnings released: EPS CN¥0.38 (vs CN¥0.37 in FY 2019)

Full year 2020 earnings released

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: HK$4.40

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

New 90-day low: HK$4.43

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Investor sentiment improved over the past week

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

First half earnings released

New 90-day low: HK$4.49

First half earnings released

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 21, 2020

New 90-day low - HK$5.12

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources